1. Home
  2. BOLD vs KORE Comparison

BOLD vs KORE Comparison

Compare BOLD & KORE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOLD
  • KORE
  • Stock Information
  • Founded
  • BOLD 2018
  • KORE 2003
  • Country
  • BOLD United States
  • KORE United States
  • Employees
  • BOLD N/A
  • KORE N/A
  • Industry
  • BOLD
  • KORE Telecommunications Equipment
  • Sector
  • BOLD
  • KORE Consumer Discretionary
  • Exchange
  • BOLD Nasdaq
  • KORE Nasdaq
  • Market Cap
  • BOLD 49.5M
  • KORE 39.8M
  • IPO Year
  • BOLD 2024
  • KORE N/A
  • Fundamental
  • Price
  • BOLD $1.96
  • KORE $2.40
  • Analyst Decision
  • BOLD Buy
  • KORE Buy
  • Analyst Count
  • BOLD 3
  • KORE 2
  • Target Price
  • BOLD $22.50
  • KORE $10.00
  • AVG Volume (30 Days)
  • BOLD 50.0K
  • KORE 44.9K
  • Earning Date
  • BOLD 04-03-2025
  • KORE 04-10-2025
  • Dividend Yield
  • BOLD N/A
  • KORE N/A
  • EPS Growth
  • BOLD N/A
  • KORE N/A
  • EPS
  • BOLD N/A
  • KORE N/A
  • Revenue
  • BOLD N/A
  • KORE $285,229,000.00
  • Revenue This Year
  • BOLD N/A
  • KORE $3.89
  • Revenue Next Year
  • BOLD N/A
  • KORE $5.35
  • P/E Ratio
  • BOLD N/A
  • KORE N/A
  • Revenue Growth
  • BOLD N/A
  • KORE 7.01
  • 52 Week Low
  • BOLD $1.95
  • KORE $1.10
  • 52 Week High
  • BOLD $15.24
  • KORE $5.45
  • Technical
  • Relative Strength Index (RSI)
  • BOLD N/A
  • KORE 55.24
  • Support Level
  • BOLD N/A
  • KORE $2.35
  • Resistance Level
  • BOLD N/A
  • KORE $2.79
  • Average True Range (ATR)
  • BOLD 0.00
  • KORE 0.21
  • MACD
  • BOLD 0.00
  • KORE -0.02
  • Stochastic Oscillator
  • BOLD 0.00
  • KORE 59.52

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

About KORE KORE Group Holdings Inc.

Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases. It offers connectivity services, location-based services, device solutions, and managed and professional services for the development and support of IoT technology for the Machine-to-Machine market. It derives revenue from IoT Connectivity services, IoT Solutions services, SIMs (IoT Connectivity), and IoT devices (IoT Solutions). Geographically, the company generates a majority of its revenue from the United States and the rest from other countries.

Share on Social Networks: